

--[006] Accordingly, the present invention provides:

- (1) a composition that retards the transformation of a hormone-dependent cancer to a non-hormone-dependent cancer, which contains a hormonal agent,
- (2) the composition according to (1) above, wherein said hormonal agent is an LH-RH derivative,
- (3) the composition according to (2) above, wherein said LH-RH derivative is an LH-RH agonist,
- (4) the composition according to (3) above, wherein said LH-RH derivative is a peptide represented by the formula:

**5-oxo-Pro-His-Trp-Ser-Tyr-Xaa-Leu-Arg-Pro-Xaa**

~~5-oxo-Pro-His-Trp-Ser-Tyr-Y-Leu-Arg-Pro-Z~~ (SEQ ID NO.: 1)

wherein ~~Y~~ **Xaa at position 6** represents a residue selected from among DLeu, DAla, DTrp, DSer(tBu), D2Nal and DHis(ImBzl); ~~Z~~ **Xaa at position 10** represents NH-C<sub>2</sub>H<sub>5</sub> or Gly-NH<sub>2</sub>, or a salt thereof,

- (5) the composition according to (3) above, wherein said LH-RH derivative is 5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro-NH-C<sub>2</sub>H<sub>5</sub> (SEQ ID NO.: 2) or an acetate thereof,
- (6) the composition according to (1) above, which contains in addition to a hormonal agent an agent that inhibits the action of a cell growth factor or a receptor thereof,
- (7) the composition according to (6) above, wherein said cell growth factor is ① EGF or a substance possessing substantially the same activity as it, ② insulin or a substance possessing substantially the same activity as it or ③ FGF or a substance possessing substantially the same activity as it,

(8) the composition according to (1) above, which is a preventive/therapeutic composition for prostatic cancer, ovarian cancer, cervical cancer or breast cancer,

(9) use of a hormonal agent for retarding the transformation of a hormone-dependent cancer to a non-hormone-dependent cancer,

(10) use of a hormonal agent for producing a pharmaceutical for retarding the transformation of a hormone-dependent cancer to a non-hormone-dependent cancer, and

(11) a method of retarding the transformation of a hormone-dependent cancer to a non-hormone-dependent cancer in a mammal carrying a hormone-dependent cancer, comprising administering a hormonal agent to said mammal. --

On pages 8-9 substitute the following for Paragraph [018]:

-- [018] As an LH-RH agonist, there may be used, for example, a peptide represented by General Formula [II]:

**5-oxo-Pro-His-Trp-Ser-Tyr-Xaa-Leu-Arg-Pro-Xaa**

~~5-oxo-Pro-His-Trp-Ser-Tyr-Y-Leu-Arg-Pro-Z~~ (SEQ ID NO.: 1)

wherein ~~Y~~ **Xaa at position 6** represents a residue selected from among DLeu, DAla, DTrp, DSer(tBu), D2Nal and DHis(ImBzl); ~~Z~~ **Xaa at position 10** represents NH-C<sub>2</sub>H<sub>5</sub> or Gly-NH<sub>2</sub>, or a salt thereof. A peptide wherein ~~Y~~ **Xaa at position 6** is DLeu and ~~Z~~ **Xaa at position 10** is NH-C<sub>2</sub>H<sub>5</sub> (leuporelin) or a salt thereof (e.g., acetate) (5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro-NH-C<sub>2</sub>H<sub>5</sub> (SEQ ID NO.: 2) or acetate thereof) is particularly preferred. --